67
Participants
Start Date
December 31, 2004
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Aplidin®
Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
Instituto Nacional de Enfermedades Neoplásicas (INEN), Surquillo
Hospital Morales Meseguer, Murcia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Hospital Universitario de Salamanca, Salamanca
"Istituto di ematologia e oncologia medica L. e. A. Seragnoli", Bologna
Ospedaliero Universitaria de Modena, Modena
Centre Hospitalier Lyon Sud, Lyon
Hôpital Saint- Louis, Paris
Institut Gustave Roussy, Villejuif
Hospital Español Auxilio Mutuo de Puerto Rico Inc., San Juan
Hospital Clinico de Barcelona, Barcelona
Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona
Lead Sponsor
PharmaMar
INDUSTRY